Nova Biomedical Adds PT/INR Test to Allegro® Analyzer

FOR IMMEDIATE RELEASE : April 7, 2020
Contact: Doug Curley
(781) 647-3700 ext. 1570
dcurley@novabio.com

Waltham, MA– Nova Biomedical announces the addition of PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. Now with the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the point-of-care. The Allegro analyser and this new PT/INR test are available now for purchase in CE regulated countries.

This upgrade allows Allegro to monitor patient coagulation therapy in addition to testing for glycemic control, kidney function, anemia, gout, and cardiac risk with a full lipids panel. PT/INR is just one of 18 tests for the Allegro platform, including HbA1c, Cholesterol, Triglycerides, Glucose, Creatinine, UACR, Hemoglobin, Hematocrit, and Uric Acid.

Allegro is a compact, fast, and simple POC analyser that features a clinically important menu of twelve measured and individually selectable tests, plus six calculated tests. All Allegro tests use easy capillary fingerstick sampling, eliminating the need for venipunctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips. Allegro’s quick six to nine-minute cartridge test times and ability to measure two cartridges simultaneously provide rapid results immediately to the physician.

Allegro is ideal for primary care settings with tests that are easily performed by non-technical personnel and feature disposable, ready-to-use cartridges and test strips. All results are ready during the patient visit, simplifying clinic workflow and producing cost savings for providers, while offering clinical benefits for patients.

Allegro is the only analyzer that can measure HbAlc, lipids, glucose, and creatinine from a capillary sample. Its innovative design comprises dual measurement bays, which offers the unique ability to measure two cartridges simultaneously, doubling throughput and improving efficiency.

Allegro's companion meters wirelessly transmit results to the analyzer, where they combine with all cartridge test results for one patient report. All results can be transmitted to electronic medical records for providers to review with patients during the visit. Having immediate results during the patient visit reduces clinic follow-up calls, letters, and patient re-visits, and improves patient satisfaction, compliance with care plans, and outcomes.

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacture of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Benelux, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.
www.novabiomedical.com